Cellspan oesophageal implant - Harvard Apparatus Regenerative Technology
Alternative Names: Cellspan-Paediatric-Oesophageal-Implant; Cellspan™ Esophageal Implant-Adult; Oesophageal stem cell implant - Harvard Apparatus Regenerative TechnologyLatest Information Update: 13 Nov 2024
At a glance
- Originator Biostage
- Developer Harvard Apparatus Regenerative Technology; Mayo Clinic
- Class Mesenchymal stem cell therapies
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Oesophageal disorders
Most Recent Events
- 28 Oct 2024 Harvard Apparatus Regenerative Technology plans a Investigator initiated trial in Esophageal atresia
- 28 Oct 2024 Harvard Apparatus Regenerative Technology and Children’s Hospital Capital institute of Pediatrics agree to co-develop Cellspan oesophageal implant in China for Oesophageal atresia
- 26 Aug 2024 Harvard Apparatus Regenerative Technology has patent protection for Cellspan oesophageal implant in China